Bajaj Healthcare Limited, has received an exclusive right for manufacturing, distribution & sales of the finished formulation of the Product Magnesium L Threonate (Magtein®) in India from the rights holder, Threotech LLC
da83ff64-1f89-48af-b376-471080f0b170.pdf (372.5 KB)
What is the expected sales value for Indian market?
As of January 2025, the market size of Magnesium L-Threonate (Magtein®) in India is estimated to be approximately ₹150 crore (₹1.5 billion).
This estimation aligns with the addressable market size reported by Bajaj Healthcare Limited when they launched Magnesium L-Threonate in the nutraceutical segment in February 2022.
In January 2025, Bajaj Healthcare secured exclusive rights from Threotech LLC to manufacture, distribute, and sell the finished formulation of Magnesium L-Threonate (Magtein®) in India.
This strategic collaboration is expected to enhance the availability and market penetration of Magtein® in the Indian market.
Globally, the Magnesium L-Threonate market was valued at approximately $110 million in 2023 and is projected to grow to around $220 million by 2032, exhibiting a compound annual growth rate (CAGR) of 8.2%.
This growth is driven by increasing awareness of cognitive health and the rising prevalence of neurodegenerative diseases.
Disc: tracking
What is the market size of Pimavanserin ( NUPLAZID®) in India?
Alkaloid Business is looking good with more headroom for growth, the formulation segment saw good growth, the API domestic market saw a negative growth, though the Alkaloid business remains a negative working capital business (raw material being provided by the government, it’s a niche business and highly regulated), the commentary was positive from the Investors presentation. I think the second point was crucial as they mentioned additional deals discussions are underway. Positive overall.
Disc:- Invested
biggest most of this company is its CTO Amit who is one of most sought name in pharma industry compliance. More than company , I am betting on Mr Amit .
Just sharing the results of Bajaj Healthcare
https://www.bseindia.com/xml-data/corpfiling/AttachLive/25ae5074-07b5-40af-8a03-118c29616065.pdf
Looks like good results
Invested and Biased
dr.vikas
Q4FY25 BAJAJ HEALTHCARE (Bajajhcare) Results analysis :-
Bajajhcare (Bajaj Healthcare) continues to scale up, and it’s a perfect turnaround story that I have seen. Disposing of the unprofitable operations while continuing to scale up the API, Formulation and opium processing business.
Revenue increased by 15% Y-o-Y for the quarter, while operating profit saw a 25 % decrease Y-o-Y. Net profit also saw a decrease, while the discontinued operations (the ones due to COVID and low demand). Keeps running on losses and adding to the book.
PAT from continued operations is profitable, while the Gross margins have improved.
Revenue breakup = API (domestic) saw a healthy growth of 11% YoY, API (exports) saw a growth of 15% YoY, while the Formulations segment saw an increase of 36% YoY. The other business it is in is the opium business (making poppy straws from alkaloids). Overall, API biz grew by 8% Y-o-Y.
Key points in the Presentation : -
Acquired Genrx Pharmaceuticals Pvt. Ltd. (for 10.8 crores) to enhance in-house formulations manufacturing across allopathic, nutraceutical, and natural products — strengthening backwards integration, product portfolio, and operational control.
The Company has secured CDMO contracts for 30 APIs with UK/EU partners. During FY25, it received 6 Certificates of Suitability (CEPs), enabling commercial supplies to begin from Q1 FY26 in regulated markets. This shows the scale up in the topline and bottomline both, while it remains in a sweet spot for the tariffs, as they are growing by securing contracts for Europe and the UK and not the USA.
Centobamate has received a favourable SEC recommendation and is now awaiting final approval from the DCGI, which is expected any time soon, marking a key step toward market introduction of this complex generic. Showing the capabilities of how it is evolving as a company is creating new and innovative drugs.
Magtein to be launched next Quarter, which will be another trigger to bottomline and topline expansion, while it has the exclusive rights to sell and distribute the product. The market for the product has a good TAM.
It has also successfully launched Pimavanserin in India through collaborations with a few pharmaceutical companies, becoming one of the early movers in India for this differentiated CNS molecule.
Commenting on the results, Anil Jain (MD) said in the Investor PPT:-
He talked about the turnaround while swinging back to profits and long-term creation. Talked about the operating leverage and the efficiencies (As it continues to scale up operation, we will see more operating leverage coming into play), One of the key developments he mentioned is the acquisition of Genrx for scaling up the business which will lead to expansion in manufacturing facilites while the company continues to build innovative products in CNS (Central Nervous System). Pimavanserin and the progress of Cenobamate show how Bajajhcare is evolving. After securing partnerships, they aim to become a trusted global pharma outsourcing partner.
Disc:- Invested so my views can be Biased, i remain a long term holder of the same. I am not SEBI REGISTERED these are my personal views.
Where their Opium Processing revenue breakup?
Any information about exodus of directors from the board?
